npj Breast Cancer (Aug 2022)

Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy

  • Anne Grabenstetter,
  • Edi Brogi,
  • Hong Zhang,
  • Pedram Razavi,
  • Jorge S. Reis-Filho,
  • Kimberly J. VanZee,
  • Larry Norton,
  • Hannah Y. Wen

DOI
https://doi.org/10.1038/s41523-022-00469-z
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Breast adenoid cystic carcinoma (AdCC) is a rare subtype of triple negative breast cancer. Two morphologic variants are described, namely classic AdCC (C-AdCC) and solid basaloid (SB-AdCC). Recent studies have shown that the SB-AdCC variant has significantly worse prognosis than C-AdCC. Due to the rarity of SB-AdCC, no standard recommendations are available for its management. Data on the use and benefit of chemotherapy in patients with SB-AdCC are sparse and the response to neoadjuvant chemotherapy has not been reported. We present the clinical and pathologic findings of a patient with SB-AdCC treated with neoadjuvant chemotherapy who achieved a remarkable pathologic response.